A pilot trial of the effect of bone antiresorptive agents on bone turnover markers in critically ill women

Author:

Orford Neil R1,Bone Allison2,Kotowicz Mark A1,Bailey Michael3,Pasco Julie A1,Maiden Matthew2,Kakho Nima2,Cattigan Claire2,Nichonghaile Martina2,Jones Claire2,Hodgson Carol3,Nair Priya4,Center Jacqueline4,Bellomo Rinaldo3

Affiliation:

1. Deakin University

2. University Hospital Geelong, Barwon Health

3. Monash University

4. St Vincent’s Hospital Sydney

Abstract

Abstract Rationale: Critical illness is associated with increased bone turnover, loss of bone density, and increased risk of fragility fractures. The impact of bone antiresorptive agents in this population is not established. Objectives: Examine the efficacy, feasibility, and safety of antiresorptive agents administered to critically ill women aged fifty years or greater. Methods: Women aged 50 years or greater admitted to an intensive care unit for at least 24 hours were randomised to receive an antiresorptive agent (zoledronic acid or denosumab) or placebo, during critical illness and six months later (denosumab only). Bone turnover markers and bone mineral density (BMD) were monitored for one year. Measurements and Main Results: We studied 18 patients over 35 months before stopping the study due to the COVID-19 pandemic. Antiresorptive medications decreased the bone turnover marker type 1 cross-linked c-telopeptide (CTX) from day 0 to 28 by 43% (+40%), compared to an increase of 26% (+ 55%) observed with placebo (absolute difference -69%, 95% CI -127% to -11%), p=0.03). Mixed linear modelling revealed differences in the month after trial drug administration between the groups in serum CTX, alkaline phosphatase, parathyroid hormone, and phosphate. Change in BMD between antiresorptive and placebo groups was not statistically analysed due to small numbers. No serious adverse events were recorded. Conclusions: In critically ill women aged 50-years and over, antiresorptive agents suppressed bone resorption markers without serious adverse events. However, recruitment was slow. Further phase 2 trials examining the efficacy of these agents are warranted and should address barriers to enrolment. Trial registration: ACTRN12617000545369, registered 18th April 2017

Publisher

Research Square Platform LLC

Reference35 articles.

1. Osteoporosis: underrated, underdiagnosed and undertreated;Nguyen TV;The Medical Journal of Australia,2004

2. Diagnosis of osteoporosis and assessment of fracture risk;Kanis JA;The Lancet,2002

3. Sambrook P, Cooper C. Osteoporosis. The Lancet. 2006;367(9527):2010–2018. doi:10.1016/s0140-6736(06)68891-0

4. The human cost of fracture;Pasco JA;Osteoporosis International,2005

5. Watts JJ, Abimanyi-Ochom J, Sanders KM. Osteoporosis Costing All Australians. A New Burden of Disease Analysis.; 2013:1–80.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3